1. Home
  2. AVXL vs PRTC Comparison

AVXL vs PRTC Comparison

Compare AVXL & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$5.18

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$19.44

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVXL
PRTC
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.6M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AVXL
PRTC
Price
$5.18
$19.44
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$22.00
N/A
AVG Volume (30 Days)
2.1M
2.4K
Earning Date
02-11-2026
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.62
Revenue Growth
N/A
1265.60
52 Week Low
$2.86
$13.30
52 Week High
$13.99
$20.00

Technical Indicators

Market Signals
Indicator
AVXL
PRTC
Relative Strength Index (RSI) 69.64 65.25
Support Level $4.67 $17.00
Resistance Level $4.44 $19.85
Average True Range (ATR) 0.29 0.47
MACD 0.19 0.23
Stochastic Oscillator 96.45 68.22

Price Performance

Historical Comparison
AVXL
PRTC

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: